2016-04-26
A comprehensive repertoire of tRNA-derived fragments in prostate cancer
Publication
Publication
Oncotarget , Volume 7 - Issue 17 p. 24766- 24777
Prostate cancer (PCa) is the most common cancer among men in developed countries. Although its genetic background is thoroughly investigated, rather littleis known about the role of small non-coding RNAs (sncRNA) in this disease. tRNA derived fragments (tRFs) represent a new class of sncRNAs, which are present ina broad range of species and have been reported to play a role in several cellular processes. Here, we analyzed the expression of tRFs in fresh frozen patient samples derived from normal adjacent prostate and different stages of PCa by RNA-sequencing. We identified 598 unique tRFs, many of which are deregulated in cancer samples when compared to normal adjacent tissue. Most of the identified tRFs are derived from the 5'-and 3'-ends of mature cytosolic tRNAs, but we also found tRFs produced from other parts of tRNAs, including pre-tRNA trailers and leaders, as well as tRFs from mitochondrial tRNAs. The 5'-derived tRFs comprise the most abundant class of tRFs ingeneral and represent the major class among upregulated tRFs. The 3'-derived tRFs types are dominant among downregulated tRFs in PCa. We validated the expressionof three tRFs using qPCR. The ratio of tRFs derived from tRNALys CTT and tRNAPheGAA emerged as a good indicator of progression-free survival and a candidate prognostic marker. This study provides a systematic catalogue of tRFs and their dysregulation in PCa and can serve as the basis for further research on the biomarker potential and functional roles of tRFs in this disease.
Additional Metadata | |
---|---|
, , , , | |
doi.org/10.18632/oncotarget.8293, hdl.handle.net/1765/86445 | |
Oncotarget | |
Organisation | Department of Urology |
Olvedy, M., Scaravilli, M., Hoogstrate, Y., Visakorpi, T., Jenster, G., & Martens-Uzunova, E. (2016). A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget, 7(17), 24766–24777. doi:10.18632/oncotarget.8293 |